Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 open-label study of Trumenba in immunocompromised participants aged 10 years and older
2018-002588-24Phase 4Completed
- Sponsor
- Pfizer
- Start
- May 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meningococcal group B vaccine in meningococcal disease and meningococcal meningitis, sponsored by Pfizer. Primary endpoints: Safety and tolerability of Trumenba and Immunogenicity of Trumenba. Started May 2021; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal diseasemeningococcal meningitis
Beyond the preview
Go deeper on 2018-002588-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002588-24.